Natural history of LGMD2A for delineating outcome measures in clinical trials
about
Relationships between grip strength, myotonia, and CTG expansion in myotonic dystrophy type 1.Reply: Dominant LGMD2A: alternative diagnosis or hidden digenism?Dominant LGMD2A: alternative diagnosis or hidden digenism?Autosomal dominant calpainopathy due to heterozygous CAPN3 c.643_663del21.Calpain 3 and CaMKIIβ signaling are required to induce HSP70 necessary for adaptive muscle growth after atrophy.
P2860
Natural history of LGMD2A for delineating outcome measures in clinical trials
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Natural history of LGMD2A for delineating outcome measures in clinical trials
@ast
Natural history of LGMD2A for delineating outcome measures in clinical trials
@en
type
label
Natural history of LGMD2A for delineating outcome measures in clinical trials
@ast
Natural history of LGMD2A for delineating outcome measures in clinical trials
@en
prefLabel
Natural history of LGMD2A for delineating outcome measures in clinical trials
@ast
Natural history of LGMD2A for delineating outcome measures in clinical trials
@en
P2093
P2860
P356
P1476
Natural history of LGMD2A for delineating outcome measures in clinical trials
@en
P2093
Bruno Eymard
Calpainopathy Study Group
Christine A M Payan
Claude Mignard
Daniel Stockholm
Françoise Fougerousse
Isabelle Richard
Jon Andoni Urtizberea
Michel Fardeau
P2860
P304
P356
10.1002/ACN3.287
P577
2016-03-04T00:00:00Z